Your browser doesn't support javascript.
loading
De novo mutations in the X-linked TFE3 gene cause intellectual disability with pigmentary mosaicism and storage disorder-like features.
Lehalle, Daphné; Vabres, Pierre; Sorlin, Arthur; Bierhals, Tatjana; Avila, Magali; Carmignac, Virginie; Chevarin, Martin; Torti, Erin; Abe, Yuichi; Bartolomaeus, Tobias; Clayton-Smith, Jill; Cogné, Benjamin; Cusco, Ivon; Duplomb, Laurence; De Bont, Eveline; Duffourd, Yannis; Duijkers, Floor; Elpeleg, Orly; Fattal, Aviva; Geneviève, David; Guillen Sacoto, Maria J; Guimier, Anne; Harris, David J; Hempel, Maja; Isidor, Bertrand; Jouan, Thibaud; Kuentz, Paul; Koshimizu, Eriko; Lichtenbelt, Klaske; Loik Ramey, Valerie; Maik, Miriam; Miyakate, Sakoto; Murakami, Yoshiko; Pasquier, Laurent; Pedro, Helio; Simone, Laurie; Sondergaard-Schatz, Krista; St-Onge, Judith; Thevenon, Julien; Valenzuela, Irene; Abou Jamra, Rami; van Gassen, Koen; van Haelst, Mieke M; van Koningsbruggen, Silvana; Verdura, Edgard; Whelan Habela, Christa; Zacher, Pia; Rivière, Jean-Baptiste; Thauvin-Robinet, Christel; Betschinger, Joerg.
Afiliación
  • Lehalle D; Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France daphne.lehalle@aphp.fr.
  • Vabres P; UF de Génétique Médicale, Département de Génétique, Groupe Hospitalier Pitié-Salpêtrière, APHP Sorbonne Université, Paris, France.
  • Sorlin A; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Bierhals T; Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.
  • Avila M; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Carmignac V; Centre de Référence MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, Bourgogne, France.
  • Chevarin M; Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.
  • Torti E; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Abe Y; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.
  • Bartolomaeus T; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Clayton-Smith J; Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.
  • Cogné B; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Cusco I; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Duplomb L; GeneDx, Gaithersburg, Maryland, USA.
  • De Bont E; Division of Neurology, National Center for Child Health and Development, Tokyo, Japan.
  • Duffourd Y; Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
  • Duijkers F; Genomic Medicine, Manchester Centre for Genomic Medicine, Manchester, Manchester, UK.
  • Elpeleg O; Division of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, Greater Manchester, UK.
  • Fattal A; Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Geneviève D; L'institut du thorax, INSERM, CNRS, Université de Nantes, Nantes, France.
  • Guillen Sacoto MJ; Department of Clinical and Molecular Genetics and Rare Disease Unit, University Hospital Vall d'Hebron, Barcelona, Spain.
  • Guimier A; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Harris DJ; Department of Pediatric Oncology, Ommelander Hospital Groningen, Scheemda, Groningen, The Netherlands.
  • Hempel M; Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France.
  • Isidor B; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Jouan T; Department of Genetics, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands.
  • Kuentz P; Monique and Jacques Roboh Department of Genetic Research, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Koshimizu E; Pediatric Neurology Institute, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
  • Lichtenbelt K; Departement de Génétique Medicale, Hôpital Arnaud de Villeneuve, CHRU Montpellier, Montpellier, France.
  • Loik Ramey V; GeneDx, Gaithersburg, Maryland, USA.
  • Maik M; Department of Genetics, Necker-Enfants Malades Hospitals, Paris, Île-de-France, France.
  • Miyakate S; Division of Genomics and Genetics, Boston Children s Hospital, Boston, Massachusetts, USA.
  • Murakami Y; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.
  • Pasquier L; Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Pedro H; L'institut du thorax, INSERM, CNRS, Université de Nantes, Nantes, France.
  • Simone L; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Sondergaard-Schatz K; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • St-Onge J; Génétique Biologique Histologie, PCBio, Centre Hospitalier Universitaire de Besancon, Besancon, France.
  • Thevenon J; Department of Human Genetics, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Kanagawa, Japan.
  • Valenzuela I; Department of Genetics, University Medical Centre Utrecht Brain Centre, Utrecht, Utrecht, The Netherlands.
  • Abou Jamra R; Division of Genomics and Genetics, Boston Children s Hospital, Boston, Massachusetts, USA.
  • van Gassen K; Hackensack Meridian Health Inc, Edison, New Jersey, USA.
  • van Haelst MM; Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
  • van Koningsbruggen S; Yabumoto Department of Intractable Disease Research, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
  • Verdura E; Service de Génétique Clinique, CLAD Ouest, CHU Rennes, Rennes, France.
  • Whelan Habela C; Hackensack Meridian Health Inc, Edison, New Jersey, USA.
  • Zacher P; Hackensack Meridian Health Inc, Edison, New Jersey, USA.
  • Rivière JB; Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Thauvin-Robinet C; INSERM LNC UMR 1231, Faculté de Médecine, Université de Bourgogne Franche-Comté, Dijon, France.
  • Betschinger J; Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
J Med Genet ; 57(12): 808-819, 2020 12.
Article en En | MEDLINE | ID: mdl-32409512
ABSTRACT

INTRODUCTION:

Pigmentary mosaicism (PM) manifests by pigmentation anomalies along Blaschko's lines and represents a clue toward the molecular diagnosis of syndromic intellectual disability (ID). Together with new insights on the role for lysosomal signalling in embryonic stem cell differentiation, mutations in the X-linked transcription factor 3 (TFE3) have recently been reported in five patients. Functional analysis suggested these mutations to result in ectopic nuclear gain of functions. MATERIALS AND

METHODS:

Subsequent data sharing allowed the clustering of de novo TFE3 variants identified by exome sequencing on DNA extracted from leucocytes in patients referred for syndromic ID with or without PM.

RESULTS:

We describe the detailed clinical and molecular data of 17 individuals harbouring a de novo TFE3 variant, including the patients that initially allowed reporting TFE3 as a new disease-causing gene. The 12 females and 5 males presented with pigmentation anomalies on Blaschko's lines, severe ID, epilepsy, storage disorder-like features, growth retardation and recognisable facial dysmorphism. The variant was at a mosaic state in at least two male patients. All variants were missense except one splice variant. Eleven of the 13 variants were localised in exon 4, 2 in exon 3, and 3 were recurrent variants.

CONCLUSION:

This series further delineates the specific storage disorder-like phenotype with PM ascribed to de novo TFE3 mutation in exons 3 and 4. It confirms the identification of a novel X-linked human condition associated with mosaicism and dysregulation within the mechanistic target of rapamycin (mTOR) pathway, as well as a link between lysosomal signalling and human development.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trastornos de la Pigmentación / Epilepsia / Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice / Discapacidad Intelectual Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Med Genet Año: 2020 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trastornos de la Pigmentación / Epilepsia / Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice / Discapacidad Intelectual Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Med Genet Año: 2020 Tipo del documento: Article País de afiliación: Francia